Uniphar

Stronger-than-expected organic growth drives an improved outlook

  • Sectors : Pharma and healthcare
  • Companies : Uniphar

Ratings and price correct at time of issue.

  • Uniphar

    Closing Price: 210c

  • RATING 27/08/19

  • PREVIOUS RATING N/A

DAVY VIEW

Uniphar’s trading update for FY2024 outlines stronger-than-expected growth in gross profits and EPS. Strong cashflows mean net debt is materially below forecast. Confidence in hitting its €200m medium-term EBITDA forecast has improved. We increase our EPS forecasts by 2% each year.

Download full report with analyst certification and important disclosures

Jan 28 2025, 07:20 GMT

Download